An FDA advisory board recommended withdrawing government approval for the breast cancer drug, Avastin. Pros and cons of the decision and its implications for FDA’s accelerated approval process to treat serious and life threatening diseases.


  • Gardiner Harris science reporter for "The New York Times" and author of the mystery novel 'Hazard.'
  • Dr. Peter Bach attending physician and director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, and a former adviser to Medicare.
  • Dr. Carolyn Hendricks a medical oncologist affiliated with Suburban Hospital in Bethesda.
  • William Hubbard former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA

Topics + Tags


comments powered by Disqus
Most Recent Shows

Friday News Roundup – International

Friday, Oct 02 2015Russia launches another round of airstrikes in Syria. In Afghanistan, fighting with the Taliban continues in Kunduz. And a Palestinian flag flies at the U.N. for the first time. A panel of journalists joins guest host Melissa Block for analysis of the week's top international news stories.

Friday News Roundup – Domestic

Friday, Oct 02 2015Nine people and a gunman are dead after a shooting at an Oregon community college. Bernie Sanders narrows the fundraising gap with Hillary Clinton in the last quarter. And Congress avoids a government shutdown – for now. A panel of journalists joins guest host Melissa Block of NPR News for analysis of the week's top national news stories.